Sector Expert: Steve Brozak

WBB Securities

Image: Steve Brozak

Steve Brozak is the managing partner and president of WBB Securities, an investment bank and financial analytical firm engaged in the biotechnology, pharmaceutical and medical device sectors. Before cofounding WBB Securities, he worked for several Wall Street firms, including Salomon Brothers, Dean Witter, Cowen & Company, and Alex. Brown & Sons. As WBB Security's Senior Equity Analyst, Brozak has been acknowledged for his investment acumen and equity research performance by the major analyst ranking systems. In 2013, he was selected as the #2 ranked analyst in the pharmaceuticals sector by the StarMine/Financial Times Industry Analyst Awards system. The Wall Street Journal distinguished Brozak as its Best on the Street Medical Equipment and Supplies financial analyst in its 19th Annual Best on the Street Survey in 2011. In 2010, Brozak received StarMine Thompson Reuters/Financial Times Best Brokerage Analyst award for his selection of top-performing companies in the biotechnology space. With a 25-year track record in banking and analysis in the life sciences space, Brozak also works as media commentator on the life sciences sector on the web, on television, and in print media. Brozak served in the United States Marine Corps and now serves on the Secretary of the Navy's Navy and Marine Corps Retiree Council, where he focuses on healthcare, benefits and other veteran issues. He received a bachelor's degree and a master's degree in business administration from Columbia University, and also holds FINRA licenses 3, 7, 8, 24, 63, 65, 79, 86, 87 and 99.



Recent Interviews

As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect from Biotech Next (5/27/15)
bnwtiter580

Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts. In this interview with The Life Sciences Report, Brozak, president and managing partner at WBB Securities, showcases six names with strong immunotherapeutic platforms that he believes have extraordinary potential to reward investors many times over.

Will Biotech Fire on All Cylinders in 2015? (12/30/14)
2015aheadroad580

Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before rebounding, essentially following the upward trend that most experts forecast. What is in store for 2015? The Life Sciences Report turned to newsletter writer John McCamant and WBB Securities' Steve Brozak for insight.

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak (11/13/14)
bloodmaze580

What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview with The Life Sciences Report. His military background, combined with 20 years as a biotech and medtech analyst, has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.

Recent Quotes

"With OMER's product, surgeons will receive a better product from a single-source, FDA-regulated company."

The Life Sciences Report Interview with Steve Brozak (12/30/14)
more >

"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront."

The Life Sciences Report Interview with Steve Brozak (12/30/14)
more >

"OMER's Omidria is FDA-approved, proven sterile and safe, and reimbursable by payers."

The Life Sciences Report Interview with Steve Brozak (11/13/14)
more >

"NBS will announce results from its Phase 2b PreSERVE-AMI trial on Nov. 17."

The Life Sciences Report Interview with Steve Brozak (11/13/14)
more >

"I think it would be easy for OMER to single-handedly take the market."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >

"NBS' initial trial data has been positive beyond expectations."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >

"We believe ATHX is still undervalued."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >

"There is exciting potential for CYTX's therapy."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >



Due to permission requirements, not all quotes are shown.